Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables

被引：198

作者：

Anderson, James R. ^{[1
]}

Cain, Kevin C. ^{[2
]}

Gelber, Richard D. ^{[3
,4
]}

机构：

[1] Univ Nebraska, Coll Publ Hlth, Omaha, NE 68182 USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 24期

关键词：

D O I：

10.1200/JCO.2008.16.1000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3913 / 3915

页数：3

共 20 条

[1] ANALYSIS OF SURVIVAL BY TUMOR RESPONSE
ANDERSON, JR
CAIN, KC
GELBER, RD
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) : 710 - 719
[2] Analysis of outcome by response flawed
Anderson, JR
Neuberg, DS
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 8122 - 8123
[3] ANDERSON JR, 1986, J CLIN ONCOL, V4, P115, DOI 10.1200/JCO.1986.4.1.115
[4] [Anonymous], 29 ANN SAN ANT BREAS
[5] BERTINO JR, 1986, J CLIN ONCOL, V4, P1
[6] DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER
BONADONNA, G
VALAGUSSA, P
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) : 10 - 15
[7] Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients
Bruzzi, P
Del Mastro, L
Sormani, MP
Bastholt, L
Danova, M
Focan, C
Fountzilas, G
Paul, J
Rosso, R
Venturini, M
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) : 5117 - 5125
[8] DOSE-RESPONSE IN THE TREATMENT OF BREAST-CANCER - A CRITICAL-REVIEW
HENDERSON, IC
HAYES, DF
GELMAN, R
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) : 1501 - 1515
[9] Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
Joensuu, H
Kellokumpu-Lehtinen, P
Bono, P
Alanko, T
Kataja, V
Asola, R
Utriainen, T
Kokko, R
Hemminki, A
Tarkkanen, M
Turpeenniemi-Hujanen, T
Jyrkkiö, S
Flander, M
Helle, L
Ingalsuo, S
Johansson, K
Jääskeläinen, A
Pajunen, M
Rauhala, M
Kaleva-Kerola, J
Salminen, T
Leinonen, M
Elomaa, I
Isola, J
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) : 809 - 820
[10] Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from southwest oncology group Randomized trials
Lara, Primo N., Jr.
Redman, Mary W.
Kelly, Karen
Edelman, Martin J.
Williamson, Stephen K.
Crowley, John J.
Gandara, David R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) : 463 - 467

← 1 2 →